NCT07100093View on ClinicalTrials.gov

Prospective, Multicenter Study on the Association Between Serum Ustekinumab Levels and Clinical, Biological and Endoscopic Remission in Patients With Crohn's Disease.

CompletedOBSERVATIONAL

Enrollment

100

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

December 30, 2021

Study Completion Date

February 25, 2022

Conditions

Ustekinumab Serum Levels in Patients With Crohn´s Disease

Interventions

PROCEDURE

Drug serum levels

Ustekinumab trough levels (prior to administration of the next dose of the drug) will be determined by enzyme-linked immunoadsorption assay (ELISA) methodology.

Trial Locations (1)

28046

Hospital Universitario La Paz, Madrid

All Listed Sponsors

lead

Hospital Universitario La Paz

OTHER